参考文献/References:
[1] Ponikowski P,Jankowska EA. Targeting iron deficiency in heart failure:existing evidence and future expectations[J]. Circ Heart Fail,2021,14(5):e008299.
[2] Beavers CJ,Ambrosy AP,Butler J,et al. Iron deficiency in heart failure:A Scientific Statement from the Heart Failure Society of America[J]. J Card Fail,2023,29(7):1059-1077.
[3] Allain F,Loizeau V,Chaufourier L,et al. Usefulness of a personalized algorithm-based discharge checklist in patients hospitalized for acute heart failure[J]. ESC Heart Fail,2020,7(3):1217-1223.
[4] Jankowska EA,Ponikowski P. Iron deficiency in heart failure:a Korea-Oriented Review[J]. Int J Heart Fail,2023,5(4):173- 183.
[5] Mentz RJ,Garg J,Rockhold FW,et al. Ferric carboxymaltose in heart failure with iron deficiency[J]. N Engl J Med,2023,389(11):975-986.
[6] Okonko DO,Mandal AK,Missouris CG,et al. Disordered iron homeostasis in chronic heart failure:prevalence,predictors,and relation to anemia,exercise capacity,and survival[J]. J Am Coll Cardiol,2011,58(12):1241-1251.
[7] Savarese G,von Haehling S,Butler J,et al. Iron deficiency and cardiovascular disease[J]. Eur Heart J,2023,44(1):14-27.
[8] Ghafourian K,Shapiro JS,Goodman L,et al. Iron and heart failure:diagnosis,therapies,and future directions[J]. JACC Basic Transl Sci,2020,5(3):300-313.
[9] Loncar G,Obradovic D,Thiele H,et al. Iron deficiency in heart failure[J]. ESC Heart Fail,2021,8(4):2368-2379.
[10] Tajes M,Diez-Lopez C,Enjuanes C,et al. Neurohormonal activation induces intracellular iron deficiency and mitochondrial dysfunction in cardiac cells[J]. Cell Biosci,2021,11(1):89.
[11] Chung YJ,Swietach P,Curtis MK,et al. Iron-deficiency anemia results in transcriptional and metabolic remodeling in the heart toward a glycolytic phenotype[J]. Front Cardiovasc Med,2020,7:616920.
[12] McDonagh TA,Metra M,Adamo M,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J,2021,42(36):3599-3726.
[13] Masini G,Graham FJ,Pellicori P,et al. Criteria for iron deficiency in patients with heart failure[J]. J Am Coll Cardiol,2022,79(4):341-351.
[14] McDonagh TA,Metra M,Adamo M,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC) With the special contribution of the Heart Failure Association(HFA) of the ESC[J]. Rev Esp Cardiol(Engl Ed),2022,75(6):523.
[15] McDonagh TA,Metra M,Adamo M,et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC) with the special contribution of the Heart Failure Association(HFA) of the ESC[J]. Eur J Heart Fail,2024,26(1):5-17.
[16] Heidenreich PA,Bozkurt B,Aguilar D,et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure:Executive Summary:A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation,2022,145(18):e876-e894.
[17] 中华医学会心血管病学分会,中国医师协会心血管内科医师分会,中国医师协会心力衰竭专业委员会,等. 中国心力衰竭诊断和治疗指南2024[J]. 中华心血管病杂志,2024,52(3):235-275.
[18] Thomas DW,Hinchliffe RF,Briggs C,et al. Guideline for the laboratory diagnosis of functional iron deficiency[J]. Br J Haematol,2013,161(5):639-648.
[19] Packer M,Anker SD,Butler J,et al. Critical re-evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure[J]. Eur J Heart Fail,2024,26(6):1298-1312.
[20] Corrigendum to ’High soluble transferrin receptor in patients with heart failure:a measure of iron deficiency and a strong predictor of mortality’[Eur J Heart Fail 2021;23:919-932][J]. Eur J Heart Fail,2022,24(3):591.
[21] Jankowska EA,Kasztura M,Sokolski M,et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure[J]. Eur Heart J,2014,35(36):2468-2476.
[22] Packer M,Anker SD,Butler J,et al. Identification of three mechanistic pathways for iron-deficient heart failure[J]. Eur Heart J,2024,45(26):2281-2293.
[23] von Haehling S,Ebner N,Evertz R,et al. Iron deficiency in heart failure:an overview[J]. JACC Heart Fail,2019,7(1):36-46.
[24] Beck-da-Silva L,Piardi D,Soder S,et al. IRON-HF study:a randomized trial to assess the effects of iron in heart failure patients with anemia[J]. Int J Cardiol,2013,168(4):3439-3442.
[25] Lewis GD,Malhotra R,Hernandez AF,et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency:the IRONOUT HF Randomized Clinical Trial[J]. Jama,2017,317(19):1958-1966.
[26] Song Z,Tang M,Tang G,et al. Oral iron supplementation in patients with heart failure:a systematic review and meta-analysis[J]. ESC Heart Fail,2022,9(5):2779-2786.
[27] Mei Z,Chen J,Luo S,et al. Comparative efficacy of intravenous and oral iron supplements for the treatment of iron deficiency in patients with heart failure:a network meta-analysis of randomized controlled trials[J]. Pharmacol Res,2022,182:106345.
[28] Suryani LD,Raharjo SB,Sagita R,et al. Oral ferrous sulphate improves functional capacity on heart failure patients with iron deficiency anemia[J]. Glob Heart,2022,17(1):81.
[29] Ponikowski P,Mentz RJ,Hernandez AF,et al. Efficacy of ferric carboxymaltose in heart failure with iron deficiency:an individual patient data meta-analysis[J]. Eur Heart J,2023,44(48):5077-5091.
[30] Anker SD,Colet JC,Filippatos G,et al. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure(FAIR-HF) study:a randomized ,placebo-controlled study of intravenous iron supplementation in patients with and without anaemia[J]. Eur J Heart Fail,2009,11(11):1084- 1091.
[31] Ponikowski P,van Veldhuisen DJ,Comin-Colet J,et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency?[J]. Eur Heart J,2015,36(11):657-668.
[32] van Veldhuisen DJ,Ponikowski P,van der Meer P,et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency[J]. Circulation,2017,136(15):1374-1383.
[33] Ponikowski P,Kirwan BA,Anker SD,et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure:a multicentre,double-blind,randomised,controlled trial[J]. Lancet,2020,396(10266):1895-1904.
[34] Filippatos G,Ponikowski P,Farmakis D,et al. Association between hemoglobin levels and efficacy of intravenous ferric carboxymaltose in patients with acute heart failure and iron deficiency:an AFFIRM-AHF Subgroup Analysis[J]. Circulation,2023,147(22):1640-1653.
[35] Kalra PR,Cleland JGF,Petrie MC,et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK(IRONMAN):an investigator-initiated,prospective,randomised,open-label,blinded-endpoint trial[J]. Lancet,2022,400(10369):2199-2209.
[36] Mentz RJ,Ambrosy AP,Ezekowitz JA,et al. Randomized placebo-controlled trial of ferric carboxymaltose in heart failure with iron deficiency:rationale and design[J]. Circ Heart Fail,2021,14(5):e008100.
[37] Jankowska EA,Tkaczyszyn M,Suchocki T,et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure:a meta-analysis of randomized controlled trials[J]. Eur J Heart Fail,2016,18(7):786-795.
[38] Anker SD,Kirwan BA,van Veldhuisen DJ,et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients:an individual patient data meta-analysis[J]. Eur J Heart Fail,2018,20(1):125-133.
[39] Graham FJ,Pellicori P,Ford I,et al. Intravenous iron for heart failure with evidence of iron deficiency:a meta-analysis of randomised trials[J]. Clin Res Cardiol,2021,110(8):1299-1307.
[40] Toblli JE,Lombra?a A,Duarte P,et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency[J]. J Am Coll Cardiol,2007,50(17):1657-1665.
[41] Okonko DO,Grzeslo A,Witkowski T,et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF:a randomized,controlled,observer-blinded trial[J]. J Am Coll Cardiol,2008,51(2):103-112.
[42] Dhoot S,Mittal S,Singh SP,et al. Effect of ferric-carboxy maltose on oxygen kinetics and functional status in heart failure patients with iron deficiency[J]. Future Sci OA,2020,6(5):FSO467.
[43] Martens P,Dupont M,Dauw J,et al. The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial[J]. Eur Heart J,2021,42(48):4905-4914.
[44] Mollace A,Macri R,Mollace R,et al. Effect of ferric carboxymaltose supplementation in patients with heart failure with preserved ejection fraction:role of attenuated oxidative stress and improved endothelial function[J]. Nutrients,2022,14(23):5057.
[45] Payán-Pernía S,Pérez-Simón JA,García-Erce JA. Ferric carboxymaltose in heart failure with iron deficiency[J]. N Engl J Med,2023,389(22):2108.
[46] Rhee JW,Yi H,Thomas D,et al. Modeling secondary iron overload cardiomyopathy with human induced pluripotent stem cell-derived cardiomyocytes[J]. Cell Rep,2020,32(2):107886.
[47] Docherty KF,Welsh P,Verma S,et al. Iron deficiency in heart failure and effect of dapagliflozin:findings from DAPA-HF[J]. Circulation,2022,146(13):980-994.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(6):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(6):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(6):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(6):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(6):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(6):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(6):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
[11]唐婷 陈明.心力衰竭合并贫血和铁缺乏的诊治进展[J].心血管病学进展,2020,(5):499.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
TANG Ting,CHEN Ming.Diagnosis and Treatment of Anemia and Iron Deficiency in Heart Failure[J].Advances in Cardiovascular Diseases,2020,(6):499.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
[12]陈美慧 韩宇博 隋艳波 樊德慧 张丹丹 王瑞楠?刘莉.铁代谢与心力衰竭关系的研究进展[J].心血管病学进展,2022,(1):23.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.006]
CHEN Meihui,HAN Yubo,SUI Yanbo,et al.The Relationship Between Iron Metabolism and Heart Failure[J].Advances in Cardiovascular Diseases,2022,(6):23.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.006]
[13]马赛 左庆娟 和丽丽 张国瑞 郭艺芳.血清铁铁调素在心衰患者中的表达其心功能的相关性分析[J].心血管病学进展,2023,(6):566.[doi:10.16806/j.cnki.issn.1004-3934.202.06.019]
MA Sai,ZUO Qing Juan,HE Lili,et al.The Correlation of Serum Iron and Hepcidin Levels with Cardiac Function?span>in Heart Failure Patients[J].Advances in Cardiovascular Diseases,2023,(6):566.[doi:10.16806/j.cnki.issn.1004-3934.202.06.019]